KURA

Company Overview — What Does Kura Oncology, Inc. Do?

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology, Inc. (KURA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Troy E. Wilson and employs approximately 130 people, headquartered in SAN DIEGO, California. With a market capitalization of $737M, KURA is one of the notable companies in the Healthcare sector.

Kura Oncology, Inc. (KURA) Stock Rating — Reduce (April 2026)

As of April 2026, Kura Oncology, Inc. receives a Reduce rating with a composite score of 25.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.KURA ranks #2,435 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Kura Oncology, Inc. ranks #301 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

KURA Stock Price and 52-Week Range

Kura Oncology, Inc. (KURA) currently trades at $8.61. The stock lost $0.24 (2.7%) in the most recent trading session. The 52-week high for KURA is $12.49, which means the stock is currently trading -31.1% from its annual peak. The 52-week low is $5.41, putting the stock 59.1% above its annual trough. Recent trading volume was 880K shares, suggesting relatively thin trading activity.

Is KURA Overvalued or Undervalued? — Valuation Analysis

Kura Oncology, Inc. (KURA) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.47x, versus the sector average of 2.75x. The price-to-sales ratio is 15.54x, compared to 1.66x for the average Healthcare stock.

At current multiples, Kura Oncology, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Kura Oncology, Inc. Profitability — ROE, Margins, and Quality Score

Kura Oncology, Inc. (KURA) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -144.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -34.1% versus the sector average of -33.1%.

On a margin basis, Kura Oncology, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -439.8% (sector: -66.1%). Net profit margin stands at -398.9%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

KURA Debt, Balance Sheet, and Financial Health

Kura Oncology, Inc. has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.06x, indicating strong short-term liquidity. Total debt on the balance sheet is $10M. Cash and equivalents stand at $95M.

KURA has a beta of 1.05, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Kura Oncology, Inc. is 44/100, reflecting average volatility within the normal range for its sector.

Kura Oncology, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Kura Oncology, Inc. reported revenue of $50M and earnings per share (EPS) of $-3.18. Net income for the quarter was $-252M. Gross margin was 100.0%. Operating income came in at $-217M.

In FY 2025, Kura Oncology, Inc. reported revenue of $67M and earnings per share (EPS) of $-3.18. Net income for the quarter was $-279M. Revenue grew 25.2% year-over-year compared to FY 2024. Operating income came in at $-304M.

In Q3 2025, Kura Oncology, Inc. reported revenue of $21M and earnings per share (EPS) of $-0.85. Net income for the quarter was $-74M. Operating income came in at $-80M.

In Q2 2025, Kura Oncology, Inc. reported revenue of $15M and earnings per share (EPS) of $-0.75. Net income for the quarter was $-66M. Operating income came in at $-73M.

Over the past 8 quarters, Kura Oncology, Inc. has reported varying levels of revenue. Investors analyzing KURA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

KURA Dividend Yield and Income Analysis

Kura Oncology, Inc. (KURA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

KURA Momentum and Technical Analysis Profile

Kura Oncology, Inc. (KURA) has a momentum factor score of 39/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

KURA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Kura Oncology, Inc. (KURA) ranks #301 out of 838 stocks based on the Blank Capital composite score. This places KURA in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing KURA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KURA vs S&P 500 (SPY) comparison to assess how Kura Oncology, Inc. stacks up against the broader market across all factor dimensions.

KURA Next Earnings Date

No upcoming earnings date has been announced for Kura Oncology, Inc. (KURA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy KURA? — Investment Thesis Summary

The quantitative profile for Kura Oncology, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 39/100, a headwind for near-term performance.

In summary, Kura Oncology, Inc. (KURA) earns a Reduce rating with a composite score of 25.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KURA stock.

Related Resources for KURA Investors

Explore more research and tools: KURA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KURA head-to-head with peers: KURA vs AZN, KURA vs SLGL, KURA vs VMD.